Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02992249 · ClinicalTrials.gov registry record
Prospective Evaluation of the ReCell® Autologous Cell Harvesting Device For Specific Compassionate Use Cases
A clinical trial, sponsored by Avita Medical.
- Completed
- Registry status
- 100
- Enrollment target
NCT02992249 is a clinical trial that has completed, run by Avita Medical. The registered enrollment target is 100 participants.
The verdict
NCT02992249 has completed, sponsored by Avita Medical.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
This is a prospective uncontrolled observational study to evaluate clinical outcomes following use of the ReCell Autologous Cell Harvesting Device (ReCell) as an adjunct for closure (re-epithelialization) as a treatment of life-threatening wounds requiring grafting for closure, and associated skin graft donor sites, in patients who lack adequate available skin to harvest for conventional grafting. Treatment with the ReCell device may be performed as part of a single operative procedure, or multiple staged procedures as deemed clinically necessary. Adverse events associated with the use of the ReCell device/cell suspension will be documented. Subjects will be followed for 1 year following ReCell treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-05 |
| Est. Completion | 2020-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02992249
The ClinicalTrials.gov registry entry for NCT02992249 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avita Medical, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02992249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02992249 about?
NCT02992249 is a clinical study titled "Prospective Evaluation of the ReCell® Autologous Cell Harvesting Device For Specific Compassionate Use Cases". This is a prospective uncontrolled observational study to evaluate clinical outcomes following use of the ReCell Autologous Cell Harvesting Device (ReCell) as an adjunct for closure (re-epithelialization) as a treatment of life-threatening wounds requiring grafting for closure, and associated skin g...
What is the current status of trial NCT02992249?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2014-05. Estimated completion is 2020-06.
Who is sponsoring clinical trial NCT02992249?
This trial is sponsored by Avita Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.